

# Mangalam Drugs and Organics Ltd.

Regd. Office : Rupam Building, 3rd Floor, 239 P. D'Mello Road, Near G. P. O. Mumbai - 400 001.

☎ 91-22-22616200 / 6300 / 8787 ☎ 91-22-22619090 • CIN : L24230MH1972PLC116413



**REF: MDOL/CS-SE/2019-20/031**

**November 26, 2019**

To,  
Listing Department  
BSE Ltd  
Phiroze Jeejeebhoy Towers,  
Dalal Street, Fort,  
Mumbai – 400 001

**Scrip Code: 532637**

Listing Department  
National Stock Exchange of India  
Limited  
“Exchange Plaza”,  
Plot No. C-1, Block G,  
Bandra - Kurla Complex,  
Bandra(E), Mumbai – 400 051

**Symbol: MANGALAM**

**Sub: Clarification for Financial Results**

**Ref: NSE Email dated November 21, 2019**

Dear Sir / Madam,

In continuation to our letters reference no. MDOL/CS-SE/2019-20/027 and MDOL/CS-SE/2019-20/028 dated November 2, 2019 and with further reference to email dated November 21, 2019 received from NSE, please find enclosed revised Un-audited Financial Results for the quarter and half year ended September 30, 2019 after revision in the formats of Un-Audited Financial Results for the Quarter and Half Year ended on September 30, 2019 as per the format prescribed by SEBI Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016. Kindly note that the Company has inadvertently not given column of half year ended September 30, 2018 and the same is required as per format prescribed by SEBI. Therefore, in the revised results the same is corrected.



Further, except the above changes, there is no revision in the Un-Audited Financial Results or Statements of Assets and Liabilities or Cash Flow Statement as on that date as submitted earlier. Pursuant to Regulation 46(3)(b) of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015 the revised Un-Audited Financial Results for the Quarter and Half Year ended on September 30, 2019 are being uploaded on the website of the Company.

We request you to take the same on your records and acknowledge receipt of the same.

Thanking You,

Yours faithfully,

**For Mangalam Drugs & Organics Limited**

**Geeta Karira**

**Company Secretary & Compliance Officer**



**Un-Audited Financial Results for the Half Year Ended 30th September 2019 approved and taken on record by the Board at their meeting dated 2nd November, 2019**

Sr.No	Particulars	Quarter Ended			Half Year Ended			(Rs. In Lacs)
		30.09.2019	30.06.2019	30.09.2018	30.09.2019	30.09.2018	31.03.2019	Year Ended
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited	

**A) Part-1 Statement of Un-Audited Financial Results for the Half Year Ended September 30, 2019**

1	Revenue from Operations	6,727.31	6,504.23	7,190.07	13,231.54	13,090.78	22,757.97
2	Other Income	3.02	3.87	3.84	6.89	6.61	31.88
3	Total Revenue(1+2)	6,730.33	6,508.10	7,193.91	13,238.43	13,097.39	22,789.65
4	Expenses						
	(a) Cost of Materials Consumed	4,566.24	4,216.94	5,471.41	8,783.18	9,181.97	16,870.26
	(b) Purchase of Stock in trade	0.00	0.00	0.00	0.00	0.00	0.00
	(c) Changes in Inventories of, Finished Goods and Stock-in-trade & Work In Progress	57.02	178.08	(658.31)	235.11	(573.20)	(1,538.93)
	(d) Employee Benefits Expenses	658.60	604.87	642.98	1,263.47	1,296.88	2,581.65
	(e) Finance Costs	274.60	265.13	174.43	539.73	382.58	864.65
	(f) Depreciation & amortization expenses	226.50	179.92	181.47	406.42	359.66	708.85
	(g) Other Expenses	833.39	958.85	1,179.20	1,792.24	2,144.05	3,876.85
	Total Expenses	6,816.36	6,403.79	6,991.18	13,020.15	12,791.94	23,363.35
5	Profit / (Loss) before exceptional & extraordinary items and tax(3-4)	113.97	104.31	202.73	218.28	305.45	(573.71)
6	Exceptional Items	0.00	0.00	0.00	0.00	0.00	0.00
7	Profit/(Loss) before extraordinary items and tax (5-6)	113.97	104.31	202.73	218.28	305.45	(573.71)
8	Extraordinary Items	0.00	0.00	0.00	0.00	0.00	0.00
9	Profit(+)/Loss (-) before tax(7-8)	113.97	104.31	202.73	218.28	305.45	(573.71)
10	Tax Expenses						
	Current Tax	33.18	30.38	29.93	63.56	65.82	0.00
	Deferred Tax	0.00	0.00	0.00	0.00	0.00	229.38
11	Net Profit(+)/Loss(-) after Tax (9-10)	80.79	73.93	172.80	154.72	239.63	(803.09)
12	Other Comprehensive income not reclassified into Profit & loss account (Net of Taxes)	0.61	0.52	0.43	1.13	0.85	1.69
13	Total Comprehensive Income	81.40	74.45	173.23	155.85	240.48	(801.40)
14	Paid-up Equity Share Capital (face value of Rs 10/- each)	1,582.82	1,582.82	1,582.82	1,582.82	1,582.82	1,582.82
15	Other Equity				8,139.33	9,175.90	7,983.48
16	Earnings Per Share (EPS) (of Rs 10/-each not annualised):						
	(a) Basic	0.51	0.47	1.09	0.98	1.51	(5.07)
	(b) Diluted	0.51	0.47	1.09	0.98	1.51	(5.07)

**Notes :**

- The above results have been prepared in accordance with Indian Accounting Standard (Ind AS) notified under section 133 of the companies Act 2013, read together with Companies (Indian Accounting Standard) Rules, 2015.
- The above results have been reviewed by the Audit Committee and thereafter, were approved & taken on record by the Board of Directors of the Company at their meeting held on November 02, 2019. The Statutory Auditors have expressed an unmodified audit opinion on these financial result.
- As the Company's business activity falls within a single primary Business Segment Viz. "Manufacturing of Bulk Drugs" and hence does not have any additional disclosure to be made under Ind AS-108 on "Operating Segments".
- The Company has implemented Ind AS 116 with retrospective effect. The impact of depreciation and unwinding of interest cost along with lease liability and right of use (Asset) on opening balance of other equity is 9.32 Lakhs. Company has created lease liability amounting to Rs 232.20 Lakhs and Right of Use Assets amounting to Rs 222.88 Lakhs
- Deferred Tax calculation as per Ind AS 12 is considered by the Company on annual basis
- Earlier period figures have been regrouped/ rearranged wherever necessary.

On behalf of Board of Directors  
For Mangalam Drugs & Organics Ltd

(Shri Govardhan M.Dhoot)  
Chairman & Managing Director  
(DIN:01240086)



Place: Mumbai  
Date: 2nd November, 2019

